NCT05938270 - A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer. | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

September 21, 2023

Primary Completion Date

February 11, 2026

Study Completion Date

February 11, 2026

Conditions

Prostate Cancer

Interventions

DRUG

Saruparib (AZD5305)

Saruparib (AZD5305) given orally once daily

DRUG

Darolutamide

Darolutamide tablet is 300mg, given BD orally, twice daily- total dose 1200mg

OTHER

No Treatment

No study treatment is to be taken by the participants in this arm. Radical prostatectomy should be performed as per local practice

Trial Locations (19)

4101

RECRUITING

Research Site, South Brisbane

6200

WITHDRAWN

Research Site, Ankara

8035

RECRUITING

Research Site, Barcelona

28041

RECRUITING

Research Site, Madrid

34010

WITHDRAWN

Research Site, Istanbul

46009

RECRUITING

Research Site, Valencia

48202

RECRUITING

Research Site, Detroit

02903

RECRUITING

Research Site, Providence

VIC 3000

RECRUITING

Research Site, Melbourne

V5Z 1M9

RECRUITING

Research Site, Vancouver

M5G 2M9

RECRUITING

Research Site, Toronto

G1J 4Z1

RECRUITING

Research Site, Québec

1066CX

RECRUITING

Research Site, Amsterdam

6525 GA

RECRUITING

Research Site, Nijmegen

08036

RECRUITING

Research Site, Barcelona

06100

WITHDRAWN

Research Site, Ankara

CB2 0QQ

RECRUITING

Research Site, Cambridge

M20 4BX

RECRUITING

Research Site, Manchester

NE7 7AF

RECRUITING

Research Site, Newcastle upon Tyne